The potential cost-effectiveness of infant pneumococcal vaccines in Australia

Vaccine

Volumn 29, Issue 45, 2011, Pages 8077-8085

  Newall, Anthony T ^a   Creighton, Prudence ^a   Philp, David J ^a   Wood, James G ^a   MacIntyre, C Raina ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Australia; Cost effectiveness; Disease burden; Economic evaluation; Otitis media; Pneumococcal conjugate vaccine; Pneumococcal infection; Streptococcus pneumoniae

Indexed keywords

PNEUMOCOCCUS 13 VACCINE; PNEUMOCOCCUS 7 VACCINE; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ARTICLE; AUSTRALIA; BACTEREMIA; COST EFFECTIVENESS ANALYSIS; GOVERNMENT; HEALTH CARE SYSTEM; MENINGITIS; OTITIS MEDIA; PRIORITY JOURNAL; QUALITY OF LIFE; SEROTYPE;

AUSTRALIA; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HUMANS; INFANT; MALE; MODELS, STATISTICAL; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES;

EID: 80053642550     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.08.050     Document Type: Article

References (49)

1. Melegaro A., Edmunds W.J., Pebody R.G., Miller E., George R. The current burden of pneumococcal disease in England and Wales. J Infect 2006, 37-48.
2. Hsu H.E., Shutt K.A., Moore M.R., Beall B.W., Bennett N.M., Craig A.S., et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med 2009, 360(3):244-256.
3. Pilishvili T., Lexau C., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010, 201(1):32-41.
4. Beutels P., Thiry N., Van Damme P. Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination - a review (2002-2006). Vaccine 2007, 25(8):1355-1367.
5. Rozenbaum M.H., Hoek AJv, Hak E., Postma M.J. Huge impact of assumptions on indirect effects on the cost-effectiveness of routine infant vaccination with 7-valent conjugate vaccine (Prevnar®). Vaccine 2010, 28(12):2367-2369.
6. Rodenburg G.D., de Greeff S.C., Jansen A.G.C.S., de Melker H.E., Schouls L.M., Hak E., et al. Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands. Emerg Infect Dis 2010, 16(5):816-823.
7. Isaacman D.J., McIntosh E.D., Reinert R.R. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int J Infect Dis 2010, 14(3):e197-e209.
8. Brotherton J., Wang H., Schaffer A. Vaccine preventable diseases and vaccination coverage in Australia 2003-2005. Commun Dis Intell 2007, 31(Suppl. 2):1-50.
9. Roche P., Krause V., Cook H., Barralet J., Coleman D., Sweeny A., et al. Invasive pneumococcal disease in Australia, 2006. Commun Dis Intell 2008, 32(1):18-30.
10. Jardine A., Menzies R.I., McIntyre P.B. Reduction in hospitalizations for pneumonia associated with the introduction of a pneumococcal conjugate vaccination schedule without a booster dose in Australia. Pediatr Infect Dis J 2010, 29(7):607-612.
11. Jardine A., Menzies R.I., Deeks S.L., Patel M.S., McIntyre P.B. The impact of pneumococcal conjugate vaccine on rates of myringotomy with ventilation tube insertion in Australia. Pediatr Infect Dis J 2009, 761-765.
12. Commonwealth Department of Health and Ageing 2006 guidelines for the pharmaceutical industry on preparation of submissions to the pharmaceutical benefits advisory committee (PBAC) version 4.1 2006, Commonwealth Department of Health and Ageing, Canberra.
13. Australian Bureau of Statistics Population by age and sex, Australian states and territories (ABS catalogue number: 3201.0) 2009, Australian Bureau of Statistics, Canberra.
14. Australian Bureau of Statistics Deaths, Australia (ABS catalogue number: 3302.0) 2008, Australian Bureau of Statistics, Canberra.
15. ® 2009, http://www.health.gov.au/internet/main/publishing.nsf/Content/pbac-psd-Pneumococcal-jul09.
16. ® 2010, http://www.health.gov.au/internet/main/publishing.nsf/Content/pbac-psd-Pneumococcal-july10.
17. Australian Department of Health and Ageing. National notifiable diseases surveillance system. [accessed 15.07.10]. http://www9.health.gov.au/cda/Source/CDA-index.cfm.
18. Australian Institute of Health and Welfare. AIHW national hospital morbidity database. http://www.aihw.gov.au/hospitals/datacubes/index.cfm.
19. Britt H.M.G.C., Charles J., Henderson J., Bayram C., Pan Y., Valenti L., et al. General practice activity in Australia 2008-09 2009, Australian Institute of Health and Welfare, Canberra.
20. Access Economics Pty Limited The cost burden of otitis media in Australia 2009, http://www.accesseconomics.com.au/publicationsreports/getreport.php?report=190%26id=244.
21. Taylor P.S., Faeth I., Marks M.K., Del Mar C.B., Skull S.A., Pezzullo M.L., et al. Cost of treating otitis media in Australia. Expert Rev Pharmacoecon Out Res 2009, 9(2):133-141.
22. Australian Institute of Health and Welfare (AIHW). State & Territories GRIM (General Record of Incidence of Mortality) Books. Canberra: Australian Institute of Health and Welfare (AIHW); 2008.
23. Whitney C.G., Pilishvili T., Farley M.M., Schaffner W., Craig A.S., Lynfield R., et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 2006, 368(October):1495-1502.
24. Vesikari T.M.D., Wysocki J.M.D., Chevallier B.M.D., Karvonen A.M.D., Czajka H.M.D., Arsene J.-P.M.D., et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J 2009, 28(April (4)):S66-S76.
25. Kieninger D.M., Kueper K., Steul K., Juergens C., Ahlers N., Baker S., et al. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine 2010, 28(25):4192-4203.
26. Prymula R., Peeters P., Chrobok V., Kriz P., Novakova E., Kaliskova E., et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 2006, 367(January (9512)):740-748.
27. Jansen A.G.S.C., Hak E., Veenhoven R.H., Damoiseaux R.A.M.J., Schilder A.G.M., Sanders E.A.M. Pneumococcal conjugate vaccines for preventing otitis media. Cochrane Database Syst Rev 2009, (2).
28. Fireman B., Black S.B., Shinefield H.R., Lee J., Lewis E., Ray P. Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr Infect Dis J 2003, 10-16.
29. Kirkham L., Wiertsema S., Mowe E., Geerlings K., Bowman J., Riley T., et al. Non-typeable haemophilus influenzae, not Streptococcus pneumoniae, is the predominant pathogen in middle ear effusion from Australian otitis-prone children (Poster). The 7th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD) 2010.
30. Brunton S. Current face of acute otitis media: Microbiology and prevalence resulting from widespread use of heptavalent pneumococcal conjugate vaccine. Clin Ther 2006, 28(1):118-123.
31. Hull B.P., McIntyre P.B. Timeliness of childhood immunisation in Australia. Vaccine 2006, 4403-4408.
32. Black S.B., Shinefield H.R., Ling S., Hansen J.R., Fireman B., Spring D., et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia. Pediatr Infect Dis J 2002, 21(January (9)):810-815.
33. Butler J.R.G., McIntyre P.B., MacIntyre C.R., Gilmour R., Howarth A.L., Sander B. The cost-effectiveness of pneumococcal conjugate vaccination in Australia. Vaccine 2004, 22(January (9-10)):1138-1149.
34. Clinical profiles for public hospitals, AR-DRG v 5.0, Australia. Canberra: Commonwealth of Australia, Department of Health and Ageing; 2004-05.
35. Clinical profiles for private hospitals, AR-DRG v 5.0, Australia. Canberra: Commonwealth of Australia, Department of Health and Ageing; 2004-05.
36. National Hospital Cost Data collection: Cost weights for AR-DRG version 5.1, round 12, public sector. Canberra: Commonwealth of Australia, Department of Health and Ageing; 2007-08.
37. Melegaro A., Edmunds W.J. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine 2004, 420:3-14.
38. Oostenbrink R., Moll H.A., Essink-Bot M.L. The EQ-5D the health utilities index for permanent sequelae after meningitis - a head-to-head comparison. J Clin Epidemiol 2002, 791-799.
39. Bedford H., de Louvois J., Halket S., Peckham C., Hurley R., Harvey D. Meningitis in infancy in England and Wales: follow up at age 5 years. Brit Med J 2001, 533-536.
40. Budget papers 1999-2000, Budget Paper No. 4 - budget estimates: Department of Education and Community Services. 1999 [accessed 28.01.10]. http://www.treasury.act.gov.au/budget/budget99/BP4/b4_15d.htm.
41. Hogan W.P. Review of pricing arrangements in residential aged care: commonwealth of Australia 2004.
42. McIntyre P.B., MacIntyre C.R., Gilmour R., Wang H. A population based study of the impact of corticosteroid therapy and delayed diagnosis on the outcome of childhood pneumococcal meningitis. Arch Dis Child 2005, 90(4):391-396.
43. Australian Institute of Health and Welfare (AIHW). National Mortality Database.
44. Melegaro A., Choi Y.H., George R., Edmunds W.J., Miller E., Gay N.J. Dynamic models of pneumococcal carriage and the impact of the heptavalent pneumococcal conjugate vaccine on invasive pneumococcal disease. BMC Infect Dis 2010, 10.
45. Williams S.R., Mernagh P.J., Lee M.H.T., Tan J.T. Changing epidemiology of invasive pneumococcal disease in Australian children after introduction of a 7-valent pneumococcal conjugate vaccine. Med J Aust 2011, 194(3):116-120.
46. De Wals P., Erickson L., Poirier B., Pepin J., Pichichero M.E. How to compare the efficacy of conjugate vaccines to prevent acute otitis media?. Vaccine 2009, 27(21):2877-2883.
47. Access Economics Pty Limited. Listen hear! The economic impact and cost of hearing loss in Australia. February 2006.
48. Casemix Data Collections. Round 12 (2007-08) cost report version 5.1; 2009 [accessed 26.10.10]. http://www.health.gov.au/internet/main/publishing.nsf/Content/Round_12-cost-reports.
49. Oh P.I., Maerov P., Pritchard D., Knowles S.R., Einarson T.R., Shear N.H. A cost-utility analysis of second-line antibiotics in the treatment of acute otitis media in children. Clin Ther 1996, 160-182.